XERS

+ Watchlist + Portfolio

Xeris Biopharma Holdings, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.78
52-Week Range: $5.25 – $10.08
Market Cap: $1.57B
P/E (TTM): —
EPS (TTM): -0.10
Dividend Yield: —

Advanced Metrics

Price/Book: 104.88
PEG Ratio: —
Return on Equity: —
Return on Assets: 6.13%
Gross Margin: 86.57%
Operating Margin: 5.62%
Profit Margin: -5.12%
Current Ratio: 1.45
Debt/Equity: —
Total Debt: $289.44M
Free Cash Flow: $52.45M
Revenue Growth: 28.70%
Earnings Growth: —
Enterprise Value: $1.74B

XERS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$110.25M	$163.91M	$203.07M	$291.85M
Cost of Revenue	$22.63M	$28.64M	$36.83M	$42.57M
Gross Profit	$87.61M	$135.27M	$166.24M	$249.28M
Research & Development	$20.97M	$22.34M	$25.56M	$31.16M
Selling, General & Admin	$137.75M	$146.09M	$163.48M	$182.37M
Operating Expenses	$169.55M	$179.28M	$199.88M	$224.38M
Operating Income	-$81.94M	-$44.01M	-$33.65M	$24.90M
EBITDA	-$69.31M	-$23.73M	-$13.99M	$42.33M
Pretax Income	-$96.08M	-$63.50M	-$57.10M	$554.00K
Income Tax	-$1.42M	-$1.25M	-$2.27M	$0.00
Net Income	-$94.66M	-$62.26M	-$54.84M	$554.00K
Diluted EPS	-0.70	-0.45	-0.37	0.00
Diluted Shares	135.63M	137.67M	146.77M	172.74M

XERS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$121.97M	$67.45M	$71.62M	$111.04M
Receivables	$30.83M	$39.20M	$40.41M	$51.05M
Inventory	$24.73M	$38.84M	$48.17M	$68.67M
Current Assets	$186.82M	$156.26M	$167.66M	$240.31M
Total Assets	$344.52M	$322.60M	$323.06M	$383.53M
Current Liabilities	$73.62M	$95.19M	$100.44M	$109.57M
Long-Term Debt	$187.07M	$190.93M	$217.01M	$220.34M
Total Debt	$198.06M	$229.19M	$271.45M	$258.10M
Total Liabilities	$299.33M	$329.38M	$352.68M	$369.84M
Retained Earnings	-$554.77M	-$617.02M	-$671.86M	-$671.31M
Shareholders' Equity	$45.19M	-$6.78M	-$29.61M	$13.69M
Working Capital	$113.20M	$61.07M	$67.22M	$130.74M
Net Debt	$65.11M	$123.48M	$160.49M	$109.29M

XERS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$102.89M	-$47.02M	-$36.98M	$28.63M
Capital Expenditure	-$524.00K	-$2.26M	-$868.00K	-$696.00K
Free Cash Flow	-$103.42M	-$49.29M	-$37.85M	$27.93M
Depreciation & Amortisation	$12.67M	$13.16M	$12.63M	$12.69M
Stock-Based Compensation	$12.16M	$10.72M	$18.36M	$22.37M
Investing Cash Flow	$34.46M	-$6.00M	$4.88M	-$696.00K
Financing Cash Flow	$127.47M	-$1.61M	$36.17M	$11.39M
Share Repurchases	-$468.00K	-$1.01M	-$3.73M	-$10.88M
Net Change in Cash	$59.04M	-$54.64M	$4.07M	$39.32M

XERS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$60.12M	$71.54M	$74.38M	$85.81M	$83.13M
Cost of Revenue	$8.73M	$11.90M	$11.00M	$10.95M	$10.57M
Gross Profit	$51.39M	$59.64M	$63.38M	$74.86M	$72.55M
Research & Development	$7.75M	$8.05M	$7.48M	$7.87M	$8.78M
Selling, General & Admin	$44.02M	$44.39M	$46.46M	$47.50M	$53.14M
Operating Expenses	$54.48M	$55.16M	$56.65M	$58.09M	$64.64M
Operating Income	-$3.09M	$4.48M	$6.73M	$16.77M	$7.92M
EBITDA	$1.23M	$8.59M	$11.08M	$21.43M	$12.33M
Pretax Income	-$9.22M	-$1.93M	$621.00K	$11.08M	$2.23M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$9.22M	-$1.93M	$621.00K	$11.08M	$2.23M
Diluted EPS	-0.06	-0.01	0.00	0.06	0.01
Diluted Shares	152.45M	159.46M	177.62M	180.07M	177.63M

XERS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$58.44M	$59.28M	$91.60M	$111.04M	$111.75M
Receivables	$46.33M	$53.05M	$53.75M	$51.05M	$56.30M
Inventory	$52.69M	$67.28M	$67.46M	$68.67M	$74.23M
Current Assets	$163.49M	$185.58M	$224.02M	$240.31M	$251.68M
Total Assets	$315.45M	$334.69M	$370.19M	$383.53M	$392.01M
Current Liabilities	$95.07M	$95.17M	$116.20M	$109.57M	$118.59M
Long-Term Debt	$217.81M	$218.63M	$219.47M	$220.34M	$221.22M
Total Debt	$268.75M	$257.22M	$257.65M	$258.10M	$258.55M
Total Liabilities	$350.58M	$353.99M	$371.05M	$369.84M	$379.00M
Retained Earnings	-$681.08M	-$683.01M	-$682.39M	-$671.31M	-$669.07M
Shareholders' Equity	-$35.13M	-$19.30M	-$861.00K	$13.69M	$13.01M
Working Capital	$68.42M	$90.41M	$107.82M	$130.74M	$133.09M
Net Debt	$171.32M	$159.34M	$127.87M	$109.29M	$109.47M

XERS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$10.03M	$182.00K	$18.43M	$20.04M	$9.87M
Capital Expenditure	-$13.00K	-$279.00K	-$71.00K	-$333.00K	-$325.00K
Free Cash Flow	-$10.04M	-$97.00K	$18.36M	$19.71M	$9.54M
Depreciation & Amortisation	$3.14M	$3.16M	$3.19M	$3.20M	$3.21M
Stock-Based Compensation	$4.44M	$5.01M	$7.64M	$5.27M	$4.14M
Investing Cash Flow	-$13.00K	-$279.00K	-$71.00K	-$333.00K	-$325.00K
Financing Cash Flow	-$3.14M	$942.00K	$13.85M	-$266.00K	-$8.84M
Share Repurchases	-$8.00M	-$860.00K	-$478.00K	-$1.54M	-$17.02M
Net Change in Cash	-$13.18M	$845.00K	$32.21M	$19.44M	$708.00K

Market Snapshot

About

Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company leveraging its formulation science expertise to develop and commercialize ready-to-use injectable and infusible drug formulations. The company's marketed products include Gvoke (glucagon injection) for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for Cushing's syndrome. Xeris focuses on improving patient outcomes through innovative drug delivery solutions.